One can stay invested in LLY stock as it still has growth prospects despite disappointing sales of Mounjaro and Zepbound in ...

A slow launch for Alzheimer's medicine Leqembi, a lackluster pipeline and a challenging drug launch environment are just a ...

With Eisai and Biogen’s Leqembi and Eli Lilly’s Kisunla launching onto the market, the 2024 Clinical Trials of Alzheimer’s ...

Eli Lilly and Co.’s recent decision to drop development at phase II of PD-1 agonist peresolimab in rheumatoid arthritis (RA) because of an inadequate benefit-risk profile brought further attention to ...

TD Cowen analyst Joseph Thome has maintained their bullish stance on ANAB stock, giving a Buy rating today. Joseph Thome’s rating is ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...

While Novo Nordisk says CagriSema will help users lose up to 25% of weight, duration will be clear when final results of its ...

Drugmaker Lupin aims to be part of the first wave of generic drugmakers to make GLP-1 receptor agonists products, used to ...

Bayer has acquired full rights to two drugs partnered with Loxo Oncology, on the same day that the biotech was taken over by Eli Lilly in an $ ... is in phase I/II testing as a rescue therapy ...

In South Korea, this candidate has already proceeded to phase I and II trials. It works by regulating the production ...

The CVU girls soccer team won its 20th state championship in program history this fall and the Redhawks had four players make ...